|
- 现金
- 222032 元
- 精华
- 285
- 帖子
- 67620
- 注册时间
- 2001-11-10
- 最后登录
- 2023-5-7
|
1楼
发表于 2002-9-20 21:17
法国的Nautilus生物公司陈述他们已经发明了新一代改良的阿尔法干扰素分子. 这种被改良的新型干扰素INF-a将具有效益显著, 半寿期长的特性从而解决了干扰素副作用, 病人不能接受, 效益小等问题. 目前这种干扰素是针对丙肝试药的,但是因为也是INF-a所以对乙肝治疗来讲将也是一个突破(如果时要成功的话), 因为拉米一类的抗病毒药物治疗乙肝并没有在免疫方面有效益,而若想真正治疗好乙肝是和免疫方面分割不开的.
附带原文:
Nautilus Biotech Announces Advancement of Improved Interferon Alpha For Hepatitis C virus infection
Date: Wed, 18 Sep 2002 06:07:49 -0400
Nautilus Biotech Announces Advancement of Improved Interferon Alpha For
Hepatitis C virus infection
PARIS, Sept. 13 /PRNewswire/ -- Nautilus Biotech today announced that it
has developed a set of improved IFN-alpha molecules, engineered to have a substantially increased half-life in order to minimize side effects and
maximize therapeutic efficacy and patient compliance.
The novel molecules, developed using Nautilus' proprietary 2D-scanning
technology for protein rational evolution, show a significantly higher level
of stability (half-life > 50x) in vitro compared to wild type interferon
alpha.
As the level of activity of natural IFN-alpha already meets market
expectations and patient needs, and given the strong possibility that
multiple secondary effects are tightly linked to the activity of interferon, Nautilus Biotech set out to develop products with improved stability.
"Improved stability is a key objective for the improvement of interferon
alpha, as it will increase the half-life of the molecule in the body and
decrease the frequency of repeat treatments. This is one of the most
important clinical criteria for any next generation product. Our results have been achieved without the use of PEGylation technology, and thus offer a
manufacturing advantage, less variation in product and hopefully a lower
regulatory burden " said Manuel Vega, Nautilus CEO.
At the same time Nautilus has filed a key patent application in the US
covering its 2D-scanning technology, used to create the optimised IFN-alpha. "Nautilus' unique scanning approach is the first and only rational, function & structure-based protein optimization method," said Dr Lila Drittanti Nautilus' VP of R&D. "It blends a number of computational methods into a rational predictive tool together with experimental high-throughput mutagenesis, protein expression and cell-based assays and is a powerful process for the creation of new intellectual property." This new patent application further strengthens Nautilus' proprietary technology platform in the field of rational evolution.
Nautilus has created a portfolio of novel interferon alpha molecules
with improved profiles. It is aggressively establishing a strong intellectual
property position covering enhanced versions of this billion dollar molecule
and is rapidly moving these products towards clinical trials.
"The program on interferon alpha is a demonstration of the power of
Nautilus' rational evolution technology to rapidly generate therapeutic
product candidates," said Keith Powell Nautilus' Executive VP for Corporate
Business Development. "We believe we have unlocked information in the
sequences of a large number of therapeutic proteins. The rapid development of IFN-alpha is the first step in the development of a pipeline of improved therapeutic proteins".
About Nautilus Biotech
Using its proprietary rational evolution technologies, Nautilus offers
its partners a high quality services for protein and cell line improvement.
Nautilus' target markets include protein pharmaceuticals, vaccines,
chemicals and agricultural products. In addition, through its in-house programs, Nautilus is strongly focused on applying its proprietary rational evolution technologies to improving human protein pharmaceuticals and next generation products. Corporate headquarters and R&D facilities are in Evry (France), while corporate business development is driven from its subsidiary in California.
Additional information concerning Nautilus Biotech can be obtained from
either http://www.nautilusbiotech.com or by e-mail:
[email protected]
|
|
